Clinical Study Results
• 47.8% of participants who got anifrolumab were BICLA responders. This was
86 out of 180 participants.
• 31.5% of the participants who got the placebo were BICLA responders. This
was 57 out of 182 participants.
The chart below shows the results.
Percentage of BICLA responders
after 52 weeks
60
)%(
47.8%
50 stnapicitrap
40
31.5%
30
fo
20 egatnecreP
10
0
Anifrolumab Placebo
7